Articles

RSS

West Lafayette, IN - BASi continues to expand their bioanalytical services in the area of large molecule bioanalysis; protein-based and oligonucleotide-based therapeutics. BASi offers ligand binding assays (LBA) which are ideal for macromolecular drug therapeutics, immunogenicity screening and biomarkers in biological matrices. Enzyme immunoassays (EIA) or enzyme-linked immunosorbent assay (ELISA)-based applications are our primary tools for these services.

"During our research we identified and recognized a strong demand for large molecule drug development. The need for this program allows us to partner with companies developing compounds in this arena, such as monoclonal antibody therapeutics, in order to provide biopharmaceutical companies with data that enables them to make accurate decisions on the drug development program," according to Tony Chilton, Scientific Services Chief Operating Officer. "Our large molecule program is built upon our strong foundation of experienced scientists and project managers in conjunction with the latest equipment and technology for immunoassay detection and quantification for PK/TK studies."

Large molecule biomarkers inform therapeutic decision makers on the viability of an applicant's drug and help bring new medicines to market faster. The effective use of information based on biomarker analysis potentially leads to faster decisions and reduces late-stage failures – saving pharmaceutical manufacturers time and money. BASi's experience in ligand binding services enables them to produce the right assay to meet the clinical and regulatory needs for their clients.

SOURCE: BASi